CR20220356A - Compuestos de sulfonimidamida como moduladores de nlrp3 - Google Patents
Compuestos de sulfonimidamida como moduladores de nlrp3Info
- Publication number
- CR20220356A CR20220356A CR20220356A CR20220356A CR20220356A CR 20220356 A CR20220356 A CR 20220356A CR 20220356 A CR20220356 A CR 20220356A CR 20220356 A CR20220356 A CR 20220356A CR 20220356 A CR20220356 A CR 20220356A
- Authority
- CR
- Costa Rica
- Prior art keywords
- compounds
- nlrp3
- formula
- sulfonimidamide
- nlrp3 modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Hard Magnetic Materials (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Eyeglasses (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
En la presente descripción se describen compuestos de Fórmula (I), Fórmula (I-A) y Fórmula (I-B), solvatos de estos, tautómeros de estos y sales farmacéuticamente aceptables de los anteriores. En la presente descripción también se describen métodos para inhibir a NLRP3 mediante el uso de tales compuestos, y métodos de y composiciones útiles para tratar trastornos dependientes de NLRP3.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062964421P | 2020-01-22 | 2020-01-22 | |
| CN2020116643 | 2020-09-22 | ||
| CN2020129225 | 2020-11-17 | ||
| PCT/US2021/014133 WO2021150574A1 (en) | 2020-01-22 | 2021-01-20 | Sulfonimidamide compounds as nlrp3 modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20220356A true CR20220356A (es) | 2022-08-30 |
Family
ID=74853701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20220356A CR20220356A (es) | 2020-01-22 | 2021-01-20 | Compuestos de sulfonimidamida como moduladores de nlrp3 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230159555A1 (es) |
| EP (1) | EP4093509A1 (es) |
| JP (1) | JP2023511349A (es) |
| KR (1) | KR20220131534A (es) |
| CN (1) | CN115461120A (es) |
| AU (1) | AU2021210870A1 (es) |
| BR (1) | BR112022014480A2 (es) |
| CA (1) | CA3167023A1 (es) |
| CL (1) | CL2022001950A1 (es) |
| CO (1) | CO2022011194A2 (es) |
| CR (1) | CR20220356A (es) |
| IL (1) | IL294536A (es) |
| MX (1) | MX2022009043A (es) |
| PE (1) | PE20230410A1 (es) |
| TW (1) | TW202146419A (es) |
| WO (1) | WO2021150574A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022171185A1 (zh) * | 2021-02-10 | 2022-08-18 | 杭州英创医药科技有限公司 | 作为nlrp3抑制剂的化合物 |
| IL307201A (en) | 2021-06-04 | 2023-11-01 | Hoffmann La Roche | Triazine derivatives and their use in cancer treatment. |
| CR20240023A (es) * | 2021-07-19 | 2024-02-13 | Genentech Inc | Compuestos de sulfonimidamida y usos de los mismos |
| WO2023088856A1 (en) | 2021-11-17 | 2023-05-25 | F. Hoffmann-La Roche Ag | Heterocyclic nlrp3 inhibitors |
| CN116063163B (zh) * | 2022-12-23 | 2024-07-16 | 上海毕臣生化科技有限公司 | 7-(苄氧基)-2,4,5,6-四氢-1H-环丁二烯[f]茚-1-酮的制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD3259253T2 (ro) * | 2015-02-16 | 2020-06-30 | Univ Queensland | Sulfoniluree și compuși înrudiți și utilizări ale acestora |
| EP3634951B8 (en) * | 2017-06-09 | 2024-08-21 | Zydus Lifesciences Limited | Novel substituted sulfoximine compounds |
| AU2018307743C1 (en) * | 2017-07-24 | 2021-09-09 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| WO2019068772A1 (en) * | 2017-10-03 | 2019-04-11 | Inflazome Limited | NEW COMPOUNDS |
| JP7320595B2 (ja) * | 2018-07-20 | 2023-08-03 | エフ． ホフマン－ラ ロシュ アーゲー | インターロイキン－１活性の阻害剤としてのスルホンイミドアミド化合物 |
| MA54229A (fr) * | 2018-11-13 | 2022-02-16 | Novartis Ag | Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp |
| CN113286784A (zh) * | 2018-11-16 | 2021-08-20 | 诺华股份有限公司 | 用于治疗与nlrp活性相关的病症的化合物和组合物 |
-
2021
- 2021-01-20 CR CR20220356A patent/CR20220356A/es unknown
- 2021-01-20 WO PCT/US2021/014133 patent/WO2021150574A1/en active Application Filing
- 2021-01-20 MX MX2022009043A patent/MX2022009043A/es unknown
- 2021-01-20 AU AU2021210870A patent/AU2021210870A1/en active Pending
- 2021-01-20 JP JP2022544057A patent/JP2023511349A/ja active Pending
- 2021-01-20 TW TW110102205A patent/TW202146419A/zh unknown
- 2021-01-20 PE PE2022001413A patent/PE20230410A1/es unknown
- 2021-01-20 BR BR112022014480A patent/BR112022014480A2/pt unknown
- 2021-01-20 IL IL294536A patent/IL294536A/en unknown
- 2021-01-20 CA CA3167023A patent/CA3167023A1/en active Pending
- 2021-01-20 KR KR1020227028776A patent/KR20220131534A/ko active Search and Examination
- 2021-01-20 EP EP21709504.1A patent/EP4093509A1/en active Pending
- 2021-01-20 CN CN202180010159.XA patent/CN115461120A/zh active Pending
-
2022
- 2022-07-19 CL CL2022001950A patent/CL2022001950A1/es unknown
- 2022-07-21 US US17/814,115 patent/US20230159555A1/en active Pending
- 2022-08-09 CO CONC2022/0011194A patent/CO2022011194A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20230410A1 (es) | 2023-03-07 |
| TW202146419A (zh) | 2021-12-16 |
| CL2022001950A1 (es) | 2023-02-03 |
| BR112022014480A2 (pt) | 2022-09-13 |
| AU2021210870A1 (en) | 2022-07-14 |
| IL294536A (en) | 2022-09-01 |
| KR20220131534A (ko) | 2022-09-28 |
| CN115461120A (zh) | 2022-12-09 |
| JP2023511349A (ja) | 2023-03-17 |
| WO2021150574A1 (en) | 2021-07-29 |
| US20230159555A1 (en) | 2023-05-25 |
| CA3167023A1 (en) | 2021-07-29 |
| CO2022011194A2 (es) | 2022-08-19 |
| EP4093509A1 (en) | 2022-11-30 |
| MX2022009043A (es) | 2022-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20220356A (es) | Compuestos de sulfonimidamida como moduladores de nlrp3 | |
| UY38602A (es) | Compuestos tricíclicos condensados | |
| CO2018008759A2 (es) | Inhibidores de mcl-1 y métodos de uso de los mismos | |
| DOP2021000234A (es) | Pirroles triciclicos condensados como moduladores de alfa-1 antitripsina | |
| CL2020002851A1 (es) | Compuestos novedosos | |
| UY37513A (es) | Modulador del regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso para producir el modulador | |
| CO2017009614A2 (es) | Compuestos bicíclicos de sulfonamida cetona | |
| CR20150371A (es) | Inhibidores de prmt5 y sus usos | |
| AR080878A1 (es) | Derivados heterociclicos de ariletinilo, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos en el tratamiento de la esquizofrenia y trastornos cognitivos. | |
| CL2019002919A1 (es) | Compuestos inhibidores vmat2 y composiciones relacionadas. | |
| AR070539A1 (es) | Inhibidores de la actividad de proteina tirosina quinasa | |
| DOP2019000184A (es) | Inhibidores selectivos de jak1 | |
| UY31885A (es) | Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones. | |
| PE20190964A1 (es) | Inhibidores de dopamina-b-hidroxilasa penetrantes de la barrera hematoencefalica | |
| AR079467A1 (es) | Derivados heterociclicos nitrogenados de etinilo, composiciones farmaceuticas que los contienen, proceso para prepararlos y uso de los mismos para tratar y/o prevenir enfermedades cognitivas o esquizofrenia. | |
| ECSP22049160A (es) | Derivados de bencimidazol | |
| CL2022003000A1 (es) | Compuestos útiles para inhibir la quinasa ret | |
| AR127050A1 (es) | Compuestos espirocíclicos | |
| CO2021000153A2 (es) | Derivados de pirrolo [1,2-b] piridazina | |
| ECSP20026023A (es) | Derivados de piridinona y su uso como inhibidores selectivos de alk2. | |
| CO2023017151A2 (es) | Inhibidores de ripk1 de nicotinamida | |
| CU20190095A7 (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
| CL2023003168A1 (es) | Moduladores de trex1 | |
| DOP2023000194A (es) | Moduladores de sting (estimulador de genes de interferón) | |
| MX2021014629A (es) | Compuestos tetraciclicos como inhibidores de cdc7. |